Sunflower Pharmaceutical Group Co.,Ltd Sustainability Profile
Sunflower Pharmaceutical Group Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 2001, the company has established itself as a leader in the development and manufacturing of high-quality pharmaceutical products, including innovative generics and specialty medications. With a commitment to research and development, Sunflower Pharmaceutical Group focuses on areas such as oncology, cardiology, and neurology, offering unique formulations that cater to diverse patient needs. The company’s dedication to quality and compliance has earned it a strong market position, recognised for its contributions to healthcare advancements. Through strategic partnerships and a robust distribution network, Sunflower continues to expand its reach, making significant strides in improving global health outcomes.
DitchCarbon Score
How does Sunflower Pharmaceutical Group Co.,Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sunflower Pharmaceutical Group Co.,Ltd's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sunflower Pharmaceutical Group Co.,Ltd's reported carbon emissions
In 2024, Sunflower Pharmaceutical Group Co., Ltd reported total carbon emissions of approximately 11,793,070 kg CO2e, with Scope 1 emissions accounting for about 1,436,180 kg CO2e and Scope 2 emissions at approximately 10,356,890 kg CO2e. This marks a significant increase from 2023, where total emissions were about 5,437,020 kg CO2e, with Scope 1 emissions of approximately 425,910 kg CO2e and Scope 2 emissions of about 5,011,100 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its Scope 1 emissions by 30% from a 2020 baseline by 2030. Additionally, Sunflower is targeting a similar 30% reduction in Scope 2 emissions within the same timeframe. Furthermore, the company aspires to bring its Scope 1 and Scope 2 emissions close to zero by the middle of this decade, specifically by 2025. These commitments reflect Sunflower Pharmaceutical Group's proactive approach to addressing climate change and reducing its carbon footprint, aligning with industry standards for sustainability and emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 13,088,200 | 000,000 | 0,000,000 |
| Scope 2 | 31,484,800 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Sunflower Pharmaceutical Group Co.,Ltd's Industry?
How Carbon Intensive is Sunflower Pharmaceutical Group Co.,Ltd's Location?
Sunflower Pharmaceutical Group Co.,Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sunflower Pharmaceutical Group Co.,Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
